MIG et al. lead $6m Hemovent series-A

The round was also backed by WCTI Partners from the US, Seed Fond Aachen II, KfW Bank, NRW Bank Venture Fonds and PB Beteiligung- und Vermoegensverwaltung.

Hemovent, which has already filed a patent application for its device in several countries, will use the fresh capital for further development of its product, which is not yet market ready.

WCTI is currently establishing an affiliate company in Brussels, which will be in charge of equity and debt investments in Europe and Switzerland. MIG invested via its venture fund Fond 15.

Company
Based in Aachen and founded in 2013, Hemovent is an emerging medical device company that develops a small and portable Extra Corporeal Membrane Oxygenation (ECMO) system that supports or replaces heart and lung function in the event of cardiac and respiratory failure.

People
Hemovent – Christof Lenz (CEO).
MIG Verwaltungs – Matthias Guth (venture partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Germany
• Venture